Literature DB >> 22193543

MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.

S Donzelli1, G Fontemaggi, F Fazi, S Di Agostino, F Padula, F Biagioni, P Muti, S Strano, G Blandino.   

Abstract

p53 mutations have profound effects on non-small-cell lung cancer (NSCLC) resistance to chemotherapeutic treatments. Mutant p53 proteins are usually expressed at high levels in tumors, where they exert oncogenic functions. Here we show that p53R175H, a hotspot p53 mutant, induces microRNA (miRNA)-128-2 expression. Mutant p53 binds to the putative promoter of miR128-2 host gene, ARPP21, determining a concomitant induction of ARPP21 mRNA and miR-128-2. miR-128-2 expression in lung cancer cells inhibits apoptosis and confers increased resistance to cisplatin, doxorubicin and 5-fluorouracyl treatments. At the molecular level, miR-128-2 post-transcriptionally targets E2F5 and leads to the abrogation of its repressive activity on p21(waf1) transcription. p21(waf1) protein localizes to the cytoplasmic compartment, where it exerts an anti-apoptotic effect by preventing pro-caspase-3 cleavage. This study emphasizes miRNA-128-2 role as a master regulator in NSCLC chemoresistance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22193543      PMCID: PMC3354056          DOI: 10.1038/cdd.2011.190

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  43 in total

1.  Mutant p53 forms a complex with Sp1 on HIV-LTR DNA.

Authors:  A Chicas; P Molina; J Bargonetti
Journal:  Biochem Biophys Res Commun       Date:  2000-12-20       Impact factor: 3.575

2.  Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1.

Authors:  J Sampath; D Sun; V J Kidd; J Grenet; A Gandhi; L H Shapiro; Q Wang; G P Zambetti; J D Schuetz
Journal:  J Biol Chem       Date:  2001-08-01       Impact factor: 5.157

3.  Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast.

Authors:  S C Wong; J K Chan; K C Lee; W L Hsiao
Journal:  J Pathol       Date:  2001-05       Impact factor: 7.996

Review 4.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Authors:  A Sigal; V Rotter
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

Review 5.  Rescuing the function of mutant p53.

Authors:  A N Bullock; A R Fersht
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

6.  miR-181a and miR-630 regulate cisplatin-induced cancer cell death.

Authors:  Lorenzo Galluzzi; Eugenia Morselli; Ilio Vitale; Oliver Kepp; Laura Senovilla; Alfredo Criollo; Nicolas Servant; Caroline Paccard; Philippe Hupé; Thomas Robert; Hugues Ripoche; Vladimir Lazar; Annick Harel-Bellan; Philippe Dessen; Emmanuel Barillot; Guido Kroemer
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

Review 7.  Mutant p53: an oncogenic transcription factor.

Authors:  S Strano; S Dell'Orso; S Di Agostino; G Fontemaggi; A Sacchi; G Blandino
Journal:  Oncogene       Date:  2007-04-02       Impact factor: 9.867

8.  Physical interaction with human tumor-derived p53 mutants inhibits p63 activities.

Authors:  Sabrina Strano; Giulia Fontemaggi; Antonio Costanzo; Maria Giulia Rizzo; Olimpia Monti; Alessia Baccarini; Giannino Del Sal; Massimo Levrero; Ada Sacchi; Moshe Oren; Giovanni Blandino
Journal:  J Biol Chem       Date:  2002-03-13       Impact factor: 5.157

Review 9.  The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.

Authors:  C Cadwell; G P Zambetti
Journal:  Gene       Date:  2001-10-17       Impact factor: 3.688

10.  Physical and functional interaction between p53 mutants and different isoforms of p73.

Authors:  S Strano; E Munarriz; M Rossi; B Cristofanelli; Y Shaul; L Castagnoli; A J Levine; A Sacchi; G Cesareni; M Oren; G Blandino
Journal:  J Biol Chem       Date:  2000-09-22       Impact factor: 5.157

View more
  74 in total

Review 1.  MicroRNAs, wild-type and mutant p53: more questions than answers.

Authors:  Matthew Jones; Ashish Lal
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

2.  Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.

Authors:  Shunbin Xiong; Huolin Tu; Madhusudhan Kollareddy; Vinod Pant; Qin Li; Yun Zhang; James G Jackson; Young-Ah Suh; Ana C Elizondo-Fraire; Peirong Yang; Gilda Chau; Mehrnoosh Tashakori; Amanda R Wasylishen; Zhenlin Ju; Hilla Solomon; Varda Rotter; Bin Liu; Adel K El-Naggar; Lawrence A Donehower; Luis Alfonso Martinez; Guillermina Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

Review 3.  MicroRNA: a connecting road between apoptosis and cholesterol metabolism.

Authors:  Yogita K Adlakha; Neeru Saini
Journal:  Tumour Biol       Date:  2016-04-22

4.  Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

Authors:  Marta Geretto; Alessandra Pulliero; Camillo Rosano; Dinara Zhabayeva; Rakhmet Bersimbaev; Alberto Izzotti
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

Review 5.  Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.

Authors:  Yoav Shetzer; Alina Molchadsky; Varda Rotter
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

6.  MicroRNA-1179 inhibits glioblastoma cell proliferation and cell cycle progression via directly targeting E2F transcription factor 5.

Authors:  Xiupeng Xu; Ning Cai; Tongle Zhi; Zhongyuan Bao; Dong Wang; Yinlong Liu; Kuan Jiang; Liang Fan; Jing Ji; Ning Liu
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

7.  Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex.

Authors:  F Garibaldi; E Falcone; D Trisciuoglio; T Colombo; K Lisek; D Walerych; G Del Sal; P Paci; G Bossi; G Piaggio; A Gurtner
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

8.  Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.

Authors:  F Ganci; A Sacconi; N Bossel Ben-Moshe; V Manciocco; I Sperduti; L Strigari; R Covello; M Benevolo; E Pescarmona; E Domany; P Muti; S Strano; G Spriano; G Fontemaggi; G Blandino
Journal:  Ann Oncol       Date:  2013-10-09       Impact factor: 32.976

9.  MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia.

Authors:  Evelien Mets; Gert Van Peer; Joni Van der Meulen; Michael Boice; Tom Taghon; Steven Goossens; Pieter Mestdagh; Yves Benoit; Barbara De Moerloose; Nadine Van Roy; Bruce Poppe; Jo Vandesompele; Hans-Guido Wendel; Pieter Van Vlierberghe; Frank Speleman; Pieter Rondou
Journal:  Haematologica       Date:  2014-06-03       Impact factor: 9.941

10.  MicroRNA-128 inhibits EMT of human osteosarcoma cells by directly targeting integrin α2.

Authors:  Xinsheng Liu; Zhiyong Liang; Kehai Gao; Huazhuang Li; Guangzong Zhao; Shantao Wang; Jun Fang
Journal:  Tumour Biol       Date:  2015-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.